King's College London

Research portal

Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up

Research output: Contribution to journalArticle

D T Greenblatt, E C Benton, R W Groves, J F Setterfield

Original languageEnglish
Pages (from-to)529-32
Number of pages4
JournalClinical and Experimental Dermatology
Issue number5
PublishedJul 2016

King's Authors


Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454